New US law to materially hurt InMed's BayMedica cannabinoid business; core pharma programs unaffected

InMed Pharmaceuticals Inc.

H.R. 5371, signed into law, will prohibit BayMedica's commercial inventory of rare, non-intoxicating cannabinoids as of Nov 12, 2026, in its current form.
BayMedica is evaluating alternative supply chain options to maintain regulatory compliance.
InMed's pharmaceutical programs (INM-901 for Alzheimer's, INM-089 for AMD) are not affected by the legislation.
Company warns of material negative impact on BayMedica's contribution to consolidated financial results.
Act may be amended before Nov 12, 2026, but current form already enacted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.